Arkansas sues AstraZeneca for misleading marketing
Pharma Compliance Alert, May 28, 2008
Arkansas Attorney General Dustin McDaniel filed suit against AstraZeneca for allegedly illegal marketing and fraud relating to sales of its antipsychotic Seroquel.
The suit alleges AstraZeneca:
- Sought ghostwritten research and paid thought leaders to support its marketing aims
- Failed to reveal material facts about hypotension and cataracts
- Knew the drug to be unreasonably hazardous and dangerous
- Marketed Seroquel illegally for use in children and elderly and for depression and other psychological conditions
- Engaged in “clandestine” promotion of Seroquel for non medically necessary uses
- Engaged in “illegal direct solicitation of physicians”
McDaniel is seeking unspecified damages and civil penalties to recover money spent by the state to purchase the drug, provide care for Seroquel-related illnesses, and reimburse prescriptions for uses that weren’t medically necessary, the release states.
In addition, AstraZeneca faces approximately 8,000 lawsuits from patients who claim Seroquel caused diabetes and other injuries.
Pennsylvania and Montana are also suing AstraZeneca over Seroquel. McDaniel has previously filed suit against Eli Lilly, which sells Zyprexa, and Johnson & Johnson, which sells Risperda.
Comments
0 comments on “Arkansas sues AstraZeneca for misleading marketing ”
Related Products
-
ePharm5 InDepth
EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...
-
Big Pharma Performance Before, During and Beyond the Global Recession
This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global...
Most Popular
- Articles
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- Topic: CMS, OESS post new security compliance review information, checklist
- What does case-mix index mean to you?
- QA:Coding multiple initial infusions
- Capturing all necessary codes for IUD insertion and removal can be challenging
- News and briefs: Oklahoma Osteopathic Association against residency bill change
- OB services: Coding inside and outside of the package
- HIPAA Q&A: Level of encryption needed for email
- E-mailed
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- New conflicts of interest create new challenges
- Joint Commission Center announces handoff communication solutions
- Inside best practice: Reduce patient falls with a stoplight
- Identify modifiable risk factors to prevent patient falls
- Hospitalist-surgeon comanagement has no effect on outcomes
- HIPAA Q&A: Level of encryption needed for email
- Case Management Monthly, June 2012
- Searched